Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04328129
Other study ID # 2020-009
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 23, 2020
Est. completion date September 30, 2021

Study information

Verified date February 2022
Source Institut Pasteur
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia.


Description:

This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia. Subjects will be assessed (questionnaires and sampling) in their homes. Subjects will be asked to attend study visits at days 0, 7, 14, 21, 28, 60, 90, 180 and 360. The primary objective of the study is to evaluate the rate of intra-household secondary transmission of the virus.


Recruitment information / eligibility

Status Completed
Enrollment 245
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Primary case: laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR), or Family contact in French Guiana and Guadeloupe: person who lived in the same household as the primary case of COVID-19 when the primary case was symptomatic. A household is defined as a group of people (2 or more) living in the same accommodation (excluding residential institutions such as boarding schools, dormitories, hostels, prisons, other communities hosting grouped people), or Close contact in New-Caledonia: any individual who was in contact with a primary case, in his/her family/living environment, work/school, friends/leisure or means of transport, when the primary case was symptomatic or presymptomatic, - Affiliated or beneficiary of a social security system - Informed consent prior to initiation of any study procedures from subject (or legally authorized representative) - State of health compatible with a blood sample as defined in the protocol. Exclusion Criteria: - Inability to consent - Person under guardianship or curatorship - Known pathology or a health problem contraindicated with the collect of blood sample.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Human biological samples
Blood sample Nasopharyngeal swab.

Locations

Country Name City State
French Guiana Centre Hospitalier Andrée Rosemon Cayenne
French Guiana Institut Pasteur de la Guyane Cayenne
Guadeloupe Institut Pasteur de Guadeloupe Les Abymes
New Caledonia Institut Pasteur de Nouvelle-Calédonie Nouméa

Sponsors (7)

Lead Sponsor Collaborator
Institut Pasteur Centre Hospitalier Andrée Rosemon de Cayenne, Centre Hospitalier de la Guadeloupe, Centre Hospitalier Territorial de Nouvelle-Calédonie, Institut Pasteur de la Guadeloupe, Institut Pasteur de la Guyane, Institut Pasteur de Nouvelle-Calédonie

Countries where clinical trial is conducted

French Guiana,  Guadeloupe,  New Caledonia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the extent of the virus transmission within households The extent of the virus transmission within households will be assessed by evaluating the rate of intra-household secondary transmission of the virus 2 years
Secondary Characterization of the secondary cases The characterization of the secondary cases will be assessed by evaluating the proportion of asymptomatic forms within the household 2 years
Secondary Characterization of the secondary cases The characterization of the secondary cases will be assessed by characterizing the risk factors for coronavirus infection. 2 years
Secondary In New-Caledonia, evaluation of the extent of the virus transmission within contact persons The extent of the virus transmission within contact persons will be assessed by evaluating the rate of extended-contact secondary transmission of the virus 2 years
See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3
Completed NCT05234359 - The CHILD Cohort COVID-19 Add-On Study